Novo Nordisk is in danger!

Very terrible news for Novo Nordisk:

Novo Nordisk A/S (NOVOB), the world’s biggest insulin maker, fell the most in 14 months after U.S. regulators disclosed that a scheduled advisory panel on the diabetes treatment Tresiba will focus on cardiovascular risks.

Novo needs the medicine, a long-acting insulin also known as degludec, to wrest market share from Paris-based Sanofi (SAN)’s best-selling Lantus, which generated $5.5 billion in revenue last year, according to data compiled by Bloomberg. Novo said in September that nothing gave it concern about Tresiba’s safety.

Regulators have to be more careful: Novo realy needs this drug, really needs the multi-billion revenue. I will pay very much attention to the situation...